Boiarsky et al. demonstrated that more than two times the number of patients had co-mutated SMARCA4/KRAS NSCLC Stage IV disease upon diagnosis (14%, N = 214) vs. Stage I (5%, N = 83) (p = 0.038), and these co-mutated patients had worse outcomes across patterns of metastatic spread (i.e., the brain) [36]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.